GILGAMESH PHARMACEUTICALS Trademark

Trademark Overview


On Friday, July 29, 2022, a trademark application was filed for GILGAMESH PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the GILGAMESH PHARMACEUTICALS trademark a serial number of 97526318. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, November 21, 2023. This trademark is owned by GILGAMESH PHARMACEUTICALS, INC.. The GILGAMESH PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely, pharmaceutical and drug preparations and substances for use in treating cancer and for use in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia, sleep disorders, attention deficit disorder, autism, and longevity; Diagnostic biomarker reagents for pharmaceutical and medical purposes; predictive biomarker reagents for medical use, namely, for pharmaceuticals and drugs for use in treating cancer and in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia,...
gilgamesh pharmaceuticals

General Information


Serial Number97526318
Word MarkGILGAMESH PHARMACEUTICALS
Filing DateFriday, July 29, 2022
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, November 21, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 26, 2023

Trademark Statements


Goods and ServicesPharmaceuticals, namely, pharmaceutical and drug preparations and substances for use in treating cancer and for use in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia, sleep disorders, attention deficit disorder, autism, and longevity; Diagnostic biomarker reagents for pharmaceutical and medical purposes; predictive biomarker reagents for medical use, namely, for pharmaceuticals and drugs for use in treating cancer and in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia, sleep disorders, attention deficit disorder, autism, and longevity
Disclaimer with Predetermined Text"PHARMACEUTICALS"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes052, 051, 005, 018, 006, 044, 046
Class Status Code6 - Active
Class Status DateTuesday, August 2, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGILGAMESH PHARMACEUTICALS, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Party NameGILGAMESH PHARMACEUTICALS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Trademark Events


Event DateEvent Description
Tuesday, November 21, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 26, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 26, 2023PUBLISHED FOR OPPOSITION
Wednesday, September 6, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, August 21, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 18, 2023EXAMINER'S AMENDMENT ENTERED
Friday, August 18, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, August 18, 2023EXAMINERS AMENDMENT E-MAILED
Friday, August 18, 2023EXAMINERS AMENDMENT -WRITTEN
Thursday, May 25, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 25, 2023NON-FINAL ACTION E-MAILED
Thursday, May 25, 2023NON-FINAL ACTION WRITTEN
Tuesday, May 16, 2023ASSIGNED TO EXAMINER
Tuesday, August 2, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 2, 2022NEW APPLICATION ENTERED